Use of fk506 for the treatment of pulmonary arterial hypertension
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsEdda SPIEKERKOETTER, Marlene RABINOVITCH, Philip A. BEACHY, David SOLOW-CORDERO
Life of this patent
Estimating the term…
Abstract
A method for reducing pulmonary hypertension in a mammal that employs FK506 is provided. In certain embodiments, the method comprises administering FK506 to a mammal having pulmonary arterial hypertension associated with defective MBPR2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal.
Claims14
1-8. (canceled)
A method of treating pulmonary arterial hypertension in a patient in need thereof, the method comprising:
- administering FK506 to the patient at a daily dosage of 0.002 mg/kg of the patient's weight to 0.05 mg/kg of the patient's weight.
A method of treating pulmonary arterial hypertension in a patient in need thereof, the method comprising:
- administering FK506 to the patient at a daily dosage of 0.001 mg/kg of the patient's weight to 0.01 mg/kg of the patient's weight.
Dependencies are inferred from the claim text.